Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

[After the 2007 crisis, what about the radiotherapy centers ?]

Lançon F, Ferrari C, Viguier J.

Rev Prat. 2019 Apr;69(4):367-369. French. No abstract available.

PMID:
31626483
2.

Breast cancer screening: Impact on care pathways.

Lefeuvre D, Catajar N, Le Bihan Benjamin C, Ifrah N, De Bels F, Viguier J, Bousquet PJ.

Cancer Med. 2019 Jul;8(8):4070-4078. doi: 10.1002/cam4.2283. Epub 2019 Jun 6.

3.

Structure-function relationship between a natural cosmetic active ingredient and the olfactory receptor OR2AT4.

Verzeaux L, Richer S, Viguier J, Gofflo S, Boudier D, Aymard E, Closs B.

Int J Cosmet Sci. 2019 Apr;41(2):194-199. doi: 10.1111/ics.12526. Epub 2019 Mar 29.

PMID:
30854660
4.

Cancer care and public health policy evaluations in France: Usefulness of the national cancer cohort.

Bousquet PJ, Lefeuvre D, Tuppin P, BenDiane MK, Rocchi M, Bouée-Benhamiche E, Viguier J, Le Bihan-Benjamin C.

PLoS One. 2018 Oct 31;13(10):e0206448. doi: 10.1371/journal.pone.0206448. eCollection 2018.

5.

Current and Former Smokers: Who Wants To Be Screened?

Couraud S, Greillier L, Brignoli-Guibaudet L, Lhomel C, Viguier J, Morère JF, Eisinger F, Cortot AB.

Clin Lung Cancer. 2018 Nov;19(6):493-501. doi: 10.1016/j.cllc.2018.07.001. Epub 2018 Jul 6.

PMID:
30107977
6.

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey.

Couraud S, Cortot AB, Pivot XB, Touboul C, Lhomel C, Blay JY, Eisinger F, Viguier J, Morère JF, Greillier L.

Prev Med Rep. 2018 Apr 18;10:332-336. doi: 10.1016/j.pmedr.2018.04.009. eCollection 2018 Jun.

7.

Colon Cancer Screening Programs: Impact of an Organized Screening Strategy Assessed by the EDIFICE Surveys.

Viguier J, Morère JF, Brignoli-Guibaudet L, Lhomel C, Couraud S, Eisinger F.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):16. doi: 10.1007/s11912-017-0648-8.

PMID:
29508157
8.

Awareness and Misconceptions of Breast Cancer Risk Factors Among Laypersons and Physicians.

Morère JF, Viguier J, Couraud S, Brignoli-Guibaudet L, Lhomel C, Pivot XB, Eisinger F.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):15. doi: 10.1007/s11912-017-0647-9.

PMID:
29508148
9.

Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey.

Viguier J, Morère JF, Pivot X, Touboul C, Lhomel C, Couraud S, de La Motte Rouge T, Eisinger F.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):14. doi: 10.1007/s11912-017-0646-x.

PMID:
29508088
10.

Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence.

Greillier L, Cortot AB, Viguier J, Brignoli-Guibaudet L, Lhomel C, Eisinger F, Morère JF, Couraud S.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):18. doi: 10.1007/s11912-017-0650-1.

PMID:
29508085
11.

Decline in Cancer Screening in Vulnerable Populations? Results of the EDIFICE Surveys.

Morère JF, Eisinger F, Touboul C, Lhomel C, Couraud S, Viguier J.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):17. doi: 10.1007/s11912-017-0649-7.

PMID:
29508084
12.

Care organization in oncology

Bréchot JM, Ferrari C, Viguier J.

Rev Prat. 2017 May;67(5):557-562. French.

PMID:
30512679
13.

[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys].

Eisinger F, Pivot X, Greillier L, Couraud S, Cortot AB, Touboul C, Lhomel C, Blay JY, Morère JF, Viguier J.

Bull Cancer. 2017 Mar;104(3):258-266. doi: 10.1016/j.bulcan.2016.12.002. Epub 2017 Jan 18. Review. French.

PMID:
28108012
14.
15.

Future perspectives for cancer screening.

Viguier J.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S87-9. doi: 10.1097/CEJ.0000000000000142. Review.

PMID:
26016794
16.

Lung cancer risks, beliefs and healthcare access among the underprivileged.

Morère JF, Viguier J, Touboul C, Pivot X, Blay JY, Coscas Y, Lhomel C, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S82-6. doi: 10.1097/CEJ.0000000000000143.

PMID:
26016793
17.

Social stratification, risk factor prevalence and cancer screening attendance.

Eisinger F, Viguier J, Touboul C, Coscas Y, Pivot X, Blay JY, Lhomel C, Morère JF.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S77-81. doi: 10.1097/CEJ.0000000000000144.

PMID:
26016792
18.

Breast cancer screening controversy: too much or not enough?

Pivot X, Viguier J, Touboul C, Morère JF, Blay JY, Coscas Y, Lhomel C, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S73-6. doi: 10.1097/CEJ.0000000000000145.

PMID:
26016791
19.

Cancer screening in France: third edition of the EDIFICE survey.

Viguier J, Morère JF, Touboul C, Coscas Y, Blay JY, Lhomel C, Pivot X, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S68-72. doi: 10.1097/CEJ.0000000000000146.

PMID:
26016790
20.

Prostate cancer screening: contrasting trends.

Eisinger F, Morère JF, Touboul C, Pivot X, Coscas Y, Blay JY, Lhomel C, Viguier J.

Cancer Causes Control. 2015 Jun;26(6):949-52. doi: 10.1007/s10552-015-0573-9. Epub 2015 Mar 31.

PMID:
25822574
21.

Melanoma risk-takers: fathers and sons.

Eisinger F, Morère JF, Pivot X, Grange F, Lhomel C, Mortier L, Robert C, Saiag P, Sassolas B, Viguier J.

J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:35-8. doi: 10.1111/jdv.12901.

PMID:
25639932
22.

[Aging and cancer care in France: hospitalization requirement in 2012].

Le Bihan-Benjamin C, Bréchot JM, Bousquet PJ, Viguier J, Buzyn A, Saint-Jean O.

Bull Cancer. 2015 Feb;102(2):139-49. doi: 10.1016/j.bulcan.2014.09.002. Epub 2015 Jan 13. French.

PMID:
25609483
23.

[Mapping of the key oncology indicators available in France].

Laanani M, Vongmany N, Lafay L, Cerf NR, Le Quellec-Nathan M, Viguier J, Bousquet PJ.

Sante Publique. 2014 May-Jun;26(3):307-16. French.

PMID:
25291878
24.

Women's participation in breast cancer screening in France--an ethical approach.

Moutel G, Duchange N, Darquy S, de Montgolfier S, Papin-Lefebvre F, Jullian O, Viguier J, Sancho-Garnier H; GRED French National Cancer Institute.

BMC Med Ethics. 2014 Aug 16;15:64. doi: 10.1186/1472-6939-15-64.

25.

Accuracy of dry vaginal self-sampling for detecting high-risk human papillomavirus infection in cervical cancer screening: a cross-sectional study.

Haguenoer K, Giraudeau B, Gaudy-Graffin C, de Pinieux I, Dubois F, Trignol-Viguier N, Viguier J, Marret H, Goudeau A.

Gynecol Oncol. 2014 Aug;134(2):302-8. doi: 10.1016/j.ygyno.2014.05.026. Epub 2014 Jun 3.

PMID:
24905772
26.

[Breast cancer screening program in France: for optimization of the information].

Papin-Lefebvre F, Moutel G, Duchange N, de Montgolfier S, Sancho-Garnier H, Jullian O, Viguier J; GRED/INCa.

Rev Epidemiol Sante Publique. 2014 Apr;62(2):109-17. doi: 10.1016/j.respe.2013.12.086. Epub 2014 Mar 12. French.

PMID:
24630531
27.

[Waiting times for cancer care in four most frequent cancers in several French regions in 2011 and 2012].

Pourcel G, Ledesert B, Bousquet PJ, Ferrari C, Viguier J, Buzyn A.

Bull Cancer. 2013 Dec;100(12):1237-50. doi: 10.1684/bdc.2013.1832. French.

PMID:
24158562
28.

Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching.

Leuraud K, Jezewski-Serra D, Viguier J, Salines E.

Cancer Epidemiol. 2013 Dec;37(6):959-67. doi: 10.1016/j.canep.2013.07.008. Epub 2013 Sep 12.

PMID:
24035240
29.

The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.

Lièvre A, Artru P, Guiu M, Laurent-Puig P, Merlin JL, Sabourin JC, Viguier J, Bastie A, Seronde A, Ducreux M.

Eur J Cancer. 2013 Jun;49(9):2126-33. doi: 10.1016/j.ejca.2013.02.016. Epub 2013 Mar 6.

PMID:
23473612
30.

Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer.

Faivre J, Dancourt V, Denis B, Dorval E, Piette C, Perrin P, Bidan JM, Jard C, Jung S, Levillain R, Viguier J, Bretagne JF.

Eur J Cancer. 2012 Nov;48(16):2969-76. doi: 10.1016/j.ejca.2012.04.007. Epub 2012 May 7.

PMID:
22572481
31.

Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme.

Faivre J, Dancourt V, Manfredi S, Denis B, Durand G, Gendre I, Bidan JM, Jard C, Levillain R, Jung S, Viguier J, Dorval E.

Dig Liver Dis. 2012 Aug;44(8):700-4. doi: 10.1016/j.dld.2012.03.015. Epub 2012 Apr 26.

PMID:
22542582
32.

Increasing coverage rates for mammographic screening in France in older women--16 years of follow-up.

Eisinger F, Beck F, Viguier J, Blay JY, Coscas Y, Roussel C, Morère JF, Pivot X.

Breast J. 2011 Nov-Dec;17(6):686-8. doi: 10.1111/j.1524-4741.2011.01169.x. No abstract available.

PMID:
22050283
33.

Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy.

Cézé N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E, Lecomte T.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1305-13. doi: 10.1007/s00280-011-1610-3. Epub 2011 Mar 30.

PMID:
21448592
34.

Breast cancer screening in women aged 50-74 years: is there room for improvement?

Morère JF, Pivot X, Viguier J, Blay JY, Calazel-Benque A, Coscas Y, Roussel C, Eisinger F.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S8-S12. doi: 10.1097/01.cej.0000391562.18512.4a.

PMID:
21245683
35.

Cancer screening: reaching the limits or terra incognita? Lessons from the EDIFICE surveys.

Eisinger F, Roussel C, Morère JF, Viguier J.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S42-4. doi: 10.1097/01.cej.0000391571.79500.ab. Review.

PMID:
21245681
36.

Impact of general practitioners' sex and age on systematic recommendation for cancer screening.

Eisinger F, Pivot X, Coscas Y, Viguier J, Calazel-Benque A, Blay JY, Roussel C, Morère JF.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S39-41. doi: 10.1097/01.cej.0000391570.71877.18.

PMID:
21245680
37.

Screening for prostate cancer: growth without control.

Eisinger F, Blay JY, Pivot X, Morère JF, Coscas Y, Calazel-Benque A, Roussel C, Viguier J.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S33-5. doi: 10.1097/01.cej.0000391568.26136.bc.

PMID:
21245678
38.

Organized colorectal cancer screening programmes: how to optimize efficiency among general practitioners.

Viguier J, Calazel-Benque A, Eisinger F, Pivot X.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S26-32. doi: 10.1097/01.cej.0000391567.49006.af.

PMID:
21245677
39.

Organized colorectal cancer screening programmes: how to optimize efficiency in the general population.

Calazel-Benque A, Viguier J, Roussel C, Pivot X, Eisinger F, Blay JY, Coscas Y, Morère JF.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S20-5. doi: 10.1097/01.cej.0000391566.41383.61.

PMID:
21245676
40.

Cancer screening: more information, more action, more benefits.

Viguier J.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S2-4. doi: 10.1097/01.cej.0000391573.93084.cd. Review.

PMID:
21245675
41.

Mammography utilization in women aged 40-49 years: the French EDIFICE survey.

Pivot X, Eisinger F, Blay JY, Coscas Y, Calazel-Benque A, Viguier J, Roussel C, Morère JF.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S16-9. doi: 10.1097/01.cej.0000391565.41383.ba.

PMID:
21245674
42.

Uptake of breast cancer screening in women aged over 75 years: a controversy to come?

Eisinger F, Viguier J, Blay JY, Morère JF, Coscas Y, Roussel C, Pivot X.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S13-5. doi: 10.1097/01.cej.0000391564.03265.3f.

PMID:
21245673
43.

Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis.

Perarnau JM, Baju A, D'alteroche L, Viguier J, Ayoub J.

Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1093-8. doi: 10.1097/MEG.0b013e328338d995.

PMID:
20308910
44.

[Digital ischemia in two patients treated with gemcitabine].

Viguier JB, Solanilla A, Boulon C, Constans J, Conri C.

J Mal Vasc. 2010 Jun;35(3):185-8. doi: 10.1016/j.jmv.2009.12.032. Epub 2010 Jan 29. French.

PMID:
20116189
45.

[An image of vena cava thrombosis].

Viguier JB, Amraoui S, Solanilla A, Boulon C, Constans J, Conri C.

J Mal Vasc. 2009 Nov;34(5):372-3. doi: 10.1016/j.jmv.2009.07.086. Epub 2009 Aug 29. French. No abstract available.

PMID:
19717254
46.

[Colorectal cancer: from diagnosis to screening].

Faivre J, Lepage C, Viguier J.

Gastroenterol Clin Biol. 2009 Aug-Sep;33(8-9):660-71. doi: 10.1016/j.gcb.2009.07.008. Epub 2009 Aug 25. French.

47.

[Colorectal cancer screening programme in France, role of the National Institute of Cancer].

Viguier J, Nathan Mle Q.

Med Sci (Paris). 2009 Mar;25 Spec No 1:45-52. doi: 10.1051/medsci/2009251s45. French.

48.

Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability.

Miquel C, Jacob S, Grandjouan S, Aimé A, Viguier J, Sabourin JC, Sarasin A, Duval A, Praz F.

Oncogene. 2007 Aug 30;26(40):5919-26. Epub 2007 Mar 26.

PMID:
17384679
49.

Polyethylene glycol and prevalence of colorectal adenomas.

Dorval E, Jankowski JM, Barbieux JP, Viguier J, Bertrand P, Brondin B, Bougnoux P, Corpet DE; Association Gastro 37.

Gastroenterol Clin Biol. 2006 Oct;30(10):1196-9.

50.

Genetic effect of ERCC1 codon 118 polymorphism and confounding factors.

Ryu JS, Viguier J, Praz F.

Clin Cancer Res. 2006 Aug 1;12(15):4784; author reply 4784-5. No abstract available.

Supplemental Content

Loading ...
Support Center